Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg raises target price on Morgan Sindall

(Sharecast News) - Analysts at Berenberg raised their target price on construction firm Morgan Sindall from 4,500.0p to 5,000.0p on Thursday, stating that "strong trading conditions" had continued. Berenberg noted that since its FY24 results on 26 February, Morgan Sindall has issued three trading updates highlighting the "strong progress" it has made in various parts of its business.

Morgan Sindall's latest update came on 17 June, this time highlighting that group pre-tax profits were expected to be "significantly ahead" of previous estimates.

The German bank pointed out that Morgan Sindall management had confirmed that year-to-date trading has been "encouraging", driven by ongoing strong trading conditions in its key fit-out division, as well as by improved margins in its construction unit.

"This helped lift the shares to new record highs, although we continue to believe there is more growth to follow in time, given the various options the portfolio structure provides," said Berenberg. We increase our EPS by 11% in FY 2025 and 6% in FY 2026," said Berenberg.

Berenberg added that the stock currently trades at a 13.6x FY25 price-to-earnings ratio and 9.2x EBIT.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.